| NKG2D ligands as therapeutic targets P Spear, MR Wu, ML Sentman, CL Sentman Cancer immunity 13 (2), 8, 2013 | 329 | 2013 |
| Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy L Nissim, MR Wu, E Pery, A Binder-Nissim, HI Suzuki, D Stupp, ... Cell 171 (5), 1138-1150. e15, 2017 | 164 | 2017 |
| An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo T Zhang, MR Wu, CL Sentman The Journal of Immunology 189 (5), 2290-2299, 2012 | 155 | 2012 |
| Engineering advanced cancer therapies with synthetic biology MR Wu, B Jusiak, TK Lu Nature Reviews Cancer 19 (4), 187-195, 2019 | 102 | 2019 |
| Diphosphothreonine-specific interaction between an SQ/TQ cluster and an FHA domain in the Rad53-Dun1 kinase cascade H Lee, C Yuan, A Hammet, A Mahajan, ESW Chen, MR Wu, MI Su, ... Molecular cell 30 (6), 767-778, 2008 | 95 | 2008 |
| Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts ME Johnson, JM Mahoney, J Taroni, JL Sargent, E Marmarelis, MR Wu, ... PloS one 10 (1), e0114017, 2015 | 89 | 2015 |
| B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity MR Wu, T Zhang, AT Gacerez, TA Coupet, LR DeMars, CL Sentman The Journal of Immunology 194 (11), 5305-5311, 2015 | 77 | 2015 |
| B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity MR Wu, T Zhang, LR DeMars, CL Sentman Gene therapy 22 (8), 675-684, 2015 | 74 | 2015 |
| A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS) MR Wu, L Nissim, D Stupp, E Pery, A Binder-Nissim, K Weisinger, ... Nature communications 10 (1), 2880, 2019 | 70 | 2019 |
| Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell–treated mice ML Sentman, JM Murad, WJ Cook, MR Wu, J Reder, SH Baumeister, ... The Journal of Immunology 197 (12), 4674-4685, 2016 | 68 | 2016 |
| DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma MR Wu, T Zhang, A Alcon, CL Sentman Cancer Immunology, Immunotherapy 64, 409-418, 2015 | 51 | 2015 |
| Versatile and on-demand biologics co-production in yeast J Cao, P Perez-Pinera, K Lowenhaupt, MR Wu, O Purcell, ... Nature communications 9 (1), 77, 2018 | 40 | 2018 |
| A synthetic transcription platform for programmable gene expression in mammalian cells WCW Chen, L Gaidukov, Y Lai, MR Wu, J Cao, MJ Gutbrod, GCG Choi, ... Nature Communications 13 (1), 6167, 2022 | 24 | 2022 |
| Contact guidance and collective migration in the advancing epithelial monolayer G Lee, L Atia, B Lan, Y Sharma, L Nissim, MR Wu, E Pery, TK Lu, CY Park, ... Connective tissue research 59 (4), 309-315, 2018 | 13 | 2018 |
| Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles MR Wu, WJ Cook, T Zhang, CL Sentman Nanotechnology 25 (47), 475101, 2014 | 6 | 2014 |
| Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy B Zhu, H Yin, D Zhang, M Zhang, X Chao, L Scimeca, MR Wu Cellular & Molecular Immunology, 1-12, 2024 | 5 | 2024 |
| Decoupling NAD+ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis J Suh, H Kim, J Min, HJ Yeon, M Hemberg, L Scimeca, MR Wu, HG Kang, ... Cell Reports Medicine 5 (1), 2024 | 3 | 2024 |
| Tumor immunotherapy TKT Lu, L Nissim, MR Wu US Patent App. 15/737,829, 2019 | 2 | 2019 |
| Tumor immunotherapy TKT Lu, L Nissim, MR Wu | 1 | 2016 |
| Harnessing natural killer cell receptors for tumor immunotherapy MR Wu Dartmouth College, 2015 | 1 | 2015 |
Tong ZhangBeigene BioMapbiomap.com üzerinde doğrulanmış e-posta adresine sahip